Annovis Bio, Inc.
Annovis Bio is a clinical-stage drug platform company based in Malvern, Pennsylvania. It develops treatments for people with neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease. Its lead product candidate, buntanetap, is an orally administered compound designed to inhibit the production of neurotoxic proteins. Annovis is conducting a Phase 3 study in early Alzheimer’s patients and an open-label extension study in Parkinson’s patients. The company’s pipeline also includes ANVS405, an intravenous form of the same compound being developed for acute neurodegeneration, including traumatic brain injury and stroke. Its oral drug candidate ANVS301 is being developed to increase cognitive capability in later stages of Alzheimer’s disease and dementia.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Annovis Bio director Michael B. Hoffman bought 5 million shares at $1 each, totaling $5 million. He now directly owns 8.36 million shares and indirectly holds 223,357 shares through a family trust, according to an SEC filing.
Hoffman Michael B purchased 5,000,000 shares of Annovis Bio, Inc. (ANVS) at $1.00 ($5.00M total) on 2026-11-06.
Annovis Bio, Inc. (ANVS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Annovis Announces Launch of Proposed Public Offering MALVERN, Pa. , November 4, 2026 -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegen
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning ANVS (Annovis Bio, Inc.). Coverage has skewed bearish: 0 bullish, 2 neutral, and 7 bearish.
Recent ANVS coverage spans corporate actions, financial news and insider activity.
In the last 30 days, ANVS insiders filed 1 SEC Form 4 transaction — 1 purchase ($5.0M) and no sales. The most active reporter was Hoffman Michael B with 1 filing.
Insider purchase suggests confidence and may create modest buying pressure.
The filing signals insider buying, but it is not a company operational update; any price impact is likely limited and sentiment-driven.
The offering will likely dilute existing shareholders and put short‑term pressure on the stock.
The equity raise will likely dilute existing shareholders and put short-term pressure on the stock.
The low cash balance suggests liquidity pressure.
AlphAI scores every news story that mentions ANVS with an AI model for sentiment and relevance, and aggregates insider trades from Annovis Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Annovis Bio director Michael B. Hoffman bought 5 million shares at $1 each, totaling $5 million. He now directly owns 8.36 million shares and indirectly holds 223,357 shares through a family trust, according to an SEC filing.
Hoffman Michael B purchased 5,000,000 shares of Annovis Bio, Inc. (ANVS) at $1.00 ($5.00M total) on 2026-11-06.
Annovis Bio, Inc. (ANVS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Annovis Announces Launch of Proposed Public Offering MALVERN, Pa. , November 4, 2026 -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegen
Annovis Bio (NYSE: ANVS) priced a public offering of 19M shares, 2M pre-funded warrants, and 21M accompanying warrants, expecting $100M+ in gross proceeds. Funds will support clinical trials for Alzheimer's and Parkinson's treatments, including buntanetap, and general corporate purposes. Canaccord Genuity is the sole bookrunner.
Annovis Bio, Inc. (ANVS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 2.02 Results of Operations and Financial Condition. Annovis Bio, Inc. (the “Company”) is providing the following information about its preliminary cash and cash equivalents as of September 30, 2026. Based on preliminary estimates and currently available information, the Comp
Annovis Bio, Inc. (ANVS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year On November 3, 2026, Annovis Bio, Inc. (the “Company”) held its Special Meeting of Stockholders (the “Special Meeting”) telephonically. At the Special Meeting, among other things, the stockholders
Annovis Bio, Inc. (ANVS) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 ANNOVIS BIO, INC. RECEIVES CONTINUED LISTING STANDARD NOTICE FROM THE NYSE MALVERN, PA – October 30, 2026 – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntan
Annovis Bio (NYSE: ANVS) received a notice from the NYSE stating it is no longer compliant with listing standards due to low market capitalization. The company has 45 days to submit a plan to regain compliance within 9 months. Trading continues under the 'ANVS.BC' symbol, indicating below-criteria status.
Annovis Bio corrected its 2025 audit fee disclosure, reporting $415,000 in audit fees and $515,000 in total fees to Ernst & Young LLP. This is an increase from $375,000 in audit fees and $482,045 in total fees in 2024. The correction was filed via Form 8-K.
Annovis Bio, Inc. (ANVS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events Due to a typographical error in the Company’s proxy statement for its annual meeting of stockholders held on June 17, 2026, the Company is filing this Current Report on Form 8-K to correct the disclosure of audit fees. The corrected fees are as follows: Fee
